Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Neonc Technologies, Inc.
Stemline Therapeutics, Inc.
Australian & New Zealand Children's Haematology/Oncology Group
Blueprint Medicines Corporation
Eli Lilly and Company
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Nationwide Children's Hospital
Institut Curie
Cedars-Sinai Medical Center
Binhui Biopharmaceutical Co., Ltd.
Regeneron Pharmaceuticals
BeiGene
National Cancer Institute (NCI)
Eisai Inc.
TVAX Biomedical
Helsinn Healthcare SA
CHA University
Radiation Therapy Oncology Group
Enzon Pharmaceuticals, Inc.
University of California, San Francisco
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
Northwestern University
Clinica Universidad de Navarra, Universidad de Navarra
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University Hospital, Geneva
Memorial Sloan Kettering Cancer Center
Radiation Therapy Oncology Group
BBB-Therapeutics B.V.
Duke University
National Cancer Institute (NCI)